Fluoxetine Treatment of Children and Adolescents with Tourette's and Obsessive Compulsive Disorders: Preliminary Clinical Experience

MARK A. RIDDLE, MAUREEN T. HARDIN, ROBERT KING, LARRY SCAHILL, JOSEPH L. WOOLSTON

Research output: Contribution to journalArticlepeer-review

Abstract

Fluoxetine hydrochloride is the first selective serotonin uptake inhibitor introduced commercially in the United States. This report describes preliminary clinical experience with fluoxetine in 10 children and adolescents, aged 8 to 15 years, with primary obsessive compulsive disorder (OCD) or Tourette's syndrome (TS) plus OCD. In general, fluoxetine, which was administered from 4 to 20 weeks at a dosage of 10 or 40 mg per day, was well tolerated. Adverse effects included behavioral agitation/activation in four patients and mild gastrointestinal symptoms in two patients. No abnormalities were noted in the seven children who had follow-up EKGs. Five of the 10 patients (50%) were considered responders; their obsessive-compulsive symptoms decreased substantially during treatment with fluoxetine. Responder rates were similar in the primary OCD (two of four, 50%) and TS + OCD (three of six, 50%) groups. In conclusion, short-term fluoxetine administration appears to be safe in children and adolescents. Placebo-controlled trials are needed to further assess the efficacy of fluoxetine.

Original languageEnglish (US)
Pages (from-to)45-48
Number of pages4
JournalJournal of the American Academy of Child and Adolescent Psychiatry
Volume29
Issue number1
DOIs
StatePublished - 1990
Externally publishedYes

Keywords

  • Tourette's syndrome
  • fluoxetine
  • obsessive compulsive disorder
  • psychopharmacology

ASJC Scopus subject areas

  • Developmental and Educational Psychology
  • Psychiatry and Mental health

Fingerprint Dive into the research topics of 'Fluoxetine Treatment of Children and Adolescents with Tourette's and Obsessive Compulsive Disorders: Preliminary Clinical Experience'. Together they form a unique fingerprint.

Cite this